is...Trying to learn the ropes in OTC World is like drinking from a firehose.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SFOR IS MOVING UP QUITE A BIT TODAY...+100%
NICE TO SEE SOME MOVEMENT UP FOR A CHANGE...I THINK IT HAS BEEN THE LAST 3 DAYS...BUT YOU NEVER KNOW WHAT'S AROUND THE CORNER.
GLTA
SLAM
$$$ SFOR $$$ UP FOR THE 3RD STRAIGHT DAY...TODAY +100%
UP FAST 100% SFOR MOVING FOR THE 3RD STRAIGHT DAY
$$$SFOR$$$ UP 100% TODAY
Nice find...thanks for sharing.
GLTA
SLAM
KBEVF AND TRNF.
TRNF IS A SPINOFF AND KBEVF HAS PRODUCT IN MAJOR MARKETS.
TAKE 2...TRNF AND KBEVF BOTH ARE MOVING. TRNF IS A SPINOFF AND KBEVF HAS PRODUCT IN MAJOR MARKETS.
GLTA
Hi Pete...2 interesting ones today...TRFN and KBEVF.
Any Thoughts?
Best regards,
SLAM
Early Ask .25, plenty of time to drop before open...but this might be promising.
GLTA
SLAM
Might be old news....
https://www.newsfilecorp.com/release/49828/Ba...-LA-Weekly
Bangi, Inc.'s CMO, Dr. Matthew Knowles, Discusses Company as Part of Feature Story in LA Weekly
Los Angeles, California--(Newsfile Corp. - November 18, 2019) - BANGI, Inc. ("BANGI" or the "Company") (OTC: BNGI), a diversified investment vehicle that acquires and leases specialized real estate assets in the cannabis, hemp and CBD industries, today announced that its Chief Marketing Officer, Dr. Matthew Knowles, was featured in a recent LA Weekly story in which he discusses, amongst other things, BANGI's bright future prospects and a glimpse of his soon-to-be-launched marketing strategy. A link to the full story can be found by clicking here: LA Weekly Story Featuring BANGI.
"Matthew has recently been able to generate interest in BANGI from some of the nation's top media outlets, including Good Morning America, The New York Times, FOX News Radio and now LA Weekly," said Dr. Neil Parsan, Chairman and Chief Executive Officer of BANGI, Inc. "We believe this national attention is attributable to Matthew's recent revelation of his breast cancer and how he plans on educating patients around the globe on the efficacy of cannabis in treating the deadly disease. The expected completion of our $50 Reg A+ offering coupled with Matthew's marketing expertise should position BANGI as one of the fastest growing participants in the landgrab that the cannabis industry is currently experiencing," concluded Dr. Parsan.
Medical Marijuana Gains Widespread Acceptance for Treatment of Cancer
Cannabis has recently gained widespread acceptance from the international medical and scientific communities for being an effective treatment for a wide variety of cancers, including ceasing or reversing progress of the core disease, as well as effectively treating several of its symptoms. With more than 100 types of cancer afflicting tens of millions of people - including cancers of the lungs, skin, colon, prostate, and brain - breast cancer in both men and women continues to be the most prevalent type of this disease. It is estimated that one in eight women will, at some point in their lives, develop the disease, which is the most common type of cancer among females. It accounts for about 10-15 percent of all cases of cancer in women globally.
Scientific Studies Reveal the Medicinal Powers of Both THC and CBD
Some studies have revealed that cannabinoid receptors are overexpressed in the tumors of particular cancers, such as those of the breast, liver, lungs, and prostate. Cannabinoids from cannabis bind with these overexpressed receptors and either switch off the cell's ability to divide and replicate or simply kill it (apoptosis).
In this manner, multiple cannabinoids (CBD and THC) can work in tandem with the body's endocannabinoid system to induce cancer cell death, inhibit cell growth, or prevent the metastasis (spread)) of cancer cells. In addition, cannabinoids help prevent good, healthy cells from being damaged by neighboring or traveling cancer cells. Cannabis also delivers no major negative side effects, unlike most pharmaceutical therapies, opiates for pain management, and chemotherapy.
The potential uses of medical marijuana for cancer patients are becoming more well known among patients and oncologists. A study conducted in a state with legalized medicinal and recreational marijuana published in CANCER-- a peer-reviewed journal of the American Cancer Society -- found that approximately one quarter of surveyed patients used marijuana in the past year, mostly for physical and psychological symptoms. Another study in the Journal of Clinical Oncology found that about half of oncologists recommended medical marijuana to their cancer patients.
To be added to BANGI's investor or media lists, please call 833-BANGINC or via email at ir@bangistock.com.
Follow us on Twitter at https://twitter.com/BangiInc.
Follow us on Instagram at https://www.instagram.com/bangiinc/.
Follow us on Facebook at https://www.facebook.com/BANGI-Inc
For additional information about BANGI, please visit www.bangistock.com.
About BANGI, Inc. [OTC: BNGI]
BANGI (pronounced bon-ghee), which means "marijuana" or "hemp" in the African dialect Swahili, is a diversified investment vehicle that acquires and leases specialized real estate assets, such as cannabis farms. The Corporation combines hard asset security and long-term appreciation potential. For more information, visit www.bangistock.com.
BANGI, Inc. Forward-Looking Statements
This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than historical facts, including, without limitation, statements regarding the investment offerings and the terms thereof, are forward-looking statements. When used in this press release, words such as we "expect", "intend", "plan", "estimate", "anticipate", "believe", "should", or the negative thereof or similar terminology are generally intended to identify forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, such statements. Investors should not place undue reliance upon forward-looking statements. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
###
Contact Information:
Investor Relations
BANGI, Inc.
833-BANGINC
ir@bangistock.com
NEW 8K OUT...FULL CONTENT BELOW:
Current Report Filing (8-k)
Date : 12/10/2019 @ 8:01AM
Source : Edgar (US Regulatory)
Stock : Taronis Technologies Inc (TRNX)
Quote : 1.17 0.0 (0.00%) @ 7:50AM
Current Report Filing (8-k)
Print
Alert
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 9, 2019
TARONIS TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-35586 26-0250418
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employee
Identification No.)
300 W. Clarendon Avenue, Suite 230
Phoenix, AZ 85013
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (866-370-3835)
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock TRNX The Nasdaq Stock Market, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 1.01 Entry into a Material Definitive Agreement.
Securities Purchase Agreement
On December 9, 2019, Taronis Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (“SPA”) with institutional investors (“Investors”) pursuant to which the Company agreed to issue and sell to each Investor, and each Investor severally, but not jointly, agreed to purchase from the Company 29,412 shares of Series H Convertible Preferred Stock (“Preferred Shares”) at a price of $850 per Preferred Share, and approximately 19,608,001 Common Stock Purchase Warrants (“Warrants”) (collectively, the “Transaction Securities”) for a total gross purchase price of $25,000,000 (the “Offering”). The Preferred Shares will have a fixed conversion price of $1.50 and will be initially convertible into approximately 19,608,000 shares of Common Stock. The Warrants will be exercisable at a price of $1.50 per share for approximately 19,608,001 shares of Common Stock, representing one hundred percent (100%) of the total number of shares of common stock issuable upon conversion of the Preferred Shares. While the Investors have agreed to purchase a minimum of 29,412 Preferred Shares, such number may be adjusted, as follows: (i) the lead Investor may elect to increase the amount of Preferred Shares to be issued pursuant to the SPA by up to 15,000 and the number of Warrants to be issued will then be increased proportionately and (ii) if certain listing failures occur that cause the failure of one or more closing condition(s), which are not waived by an Investor, the amount of Preferred Shares to be issued pursuant to the SPA may be decreased to 8,235 Preferred Shares if no Investors waive the failure of such closing condition(s) and the number of Warrants to be issued will then be decreased proportionately. The closing of the Offering is contemplated to occur on or around January 31, 2019 and is subject to being approved by the Company’s shareholders at the Company’s 2019 Annual Meeting
The Special Equities Group, a division of Bradley Woods & Co. Ltd. (“SEG”) and The Benchmark Company (“Benchmark”) will act as co-placement agents for the Offering. Aegis Capital Corp. and Maxim Group, LLC will act as financial advisors for the Offering.
The above description of the SPA does not purport to be complete and is qualified in its entirety by the full text of such SPA, which is incorporated herein and attached hereto as Exhibit 10.1.
Series H Convertible Preferred Stock
The Company shall designate a new class of preferred stock as “Series H Convertible Preferred Stock” in the aggregate amount of 40,000 shares with each Preferred Share having a stated value of $1,000. At the Closing of the Offering, the Company will issue up to 40,000 Preferred Shares.
The Preferred Shares will initially mature twenty-four months from the end of the calendar month following issuance. The maturity date of the Preferred Shares will be automatically extended in the event that the Company, directly or through its current or former Subsidiary, Taronis Fuels, Inc., receives non-refundable deposits of not less than $4,500,000 pursuant to the Turkish Contract (as defined in the certificate of designations for the Preferred Shares). The Preferred Shares include an redemption right upon the occurrent of a Triggering Event (as defined in the certificate of designations for the Preferred Shares), which means that the holders have the right to require that the Company redeem all or any portion of the conversion amount of such Holder’s Series H Preferred Shares then outstanding, upon proper notice, in cash at the prices set forth in the Certificate of designations for the Preferred Shares. The Company also has the right to redeem the Series H Convertible Preferred Stock, in cash in amount equal to 125% of the Conversion Amount (as defined in the certificate of designations for the Preferred Shares), or if certain equity conditions are not satisfied at the greater of (i) 125% of the Conversion Amount (as defined in the certificate of designations for the Preferred Shares) and (ii) the product of (A) the Conversion Amount (as defined in the certificate of designations for the Preferred Shares) being redeemed and (B) the quotient determined by dividing (I) the greatest Closing Sale Price of the shares of Common Stock during the period beginning on the date immediately preceding the date the Company delivers the Company Optional Redemption Notice and ending on the Company Optional Redemption Date, by (II) the lowest Conversion Price in effect during such period, at any time, subject to complying with certain minimum redemption amounts.
The Preferred Shares will amortize monthly over their term, payable in cash or stock at the Company’s election, subject to certain conditions, all pursuant to the terms of the certificate of designations governing the terms of the Preferred Shares
The holders of the Preferred Shares do not have voting rights.
The holders of Preferred Shares shall be entitled to receive dividends, when and as declared by the Board, from time to time, in its sole discretion. From and after the occurrence of a Triggering Event (as defined in the certificate of designation for the Preferred Shares) until such time as all Triggering Events then outstanding are cured, the holders shall be entitled to receive Dividends at a rate of eighteen percent (18.0%) per annum, which dividends shall be computed on the basis of a 360-day year and twelve 30-day months and shall compound each calendar month.
Upon the occurrence of a Triggering Event, the holder may require the Company to redeem all or any of the Preferred Shares in cash by wire transfer of immediately available funds at a price equal to the greater of (x) 118% of the Conversion Amount being redeemed and (y) the product of (A) the Conversion Amount being redeemed and (B) the quotient determined by dividing (I) the greatest Closing Sale Price of the shares of Common Stock during the period beginning on the date immediately preceding such Triggering Event and ending on the date such Holder delivers the Triggering Event Redemption Notice, by (II) the lowest Conversion Price in effect during such period. Upon a Price Triggering Event (as defined in the certificate of designations for the Preferred Shares) the Company will prepay the Preferred Shares in cash or stock or in a combination of cash and stock at the Company’s election, subject to certain conditions, all pursuant to the terms of the certificate of designations governing the terms of the Preferred Shares.
The above description of the “Series H Convertible Preferred Stock” does not purport to be complete and is qualified in its entirety by the full text of such Series H Convertible Preferred Stock, which is incorporated herein and attached hereto as Exhibit 4.1.
Warrants
Additionally, pursuant to the terms of the SPA, the Company will grant the Investors Warrants to purchase a minimum of approximately 5,490,000 shares and up to a maximum of approximately 26,666,667 shares of Common Stock, representing one hundred percent (100%) of the total number of shares of common stock issuable upon conversion of the Preferred Shares. The Warrants will be exercisable, in whole or in part, at any time after the Issuance Date at an exercise price of $1.50 per share (the “Exercise Price”). The Warrants will be exercisable for 60 months following the Issuance Date.
If on or after the Issuance Date, in event there is no effective registration statement registering, or no current prospectus is available for the resale of, the Warrant Shares, the Investors may exercise the Warrants by means of a “cashless exercise”. A holder of Warrants will not have the right to exercise any portion of its Warrants if such holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to such exercise (the “Beneficial Ownership Limitation”); provided, however, that each holder may increase or decrease the Beneficial Ownership Limitation by giving notice to the Company; provided, further, that any increase of the Beneficial Ownership Limitation will only take effect upon 61 days’ prior notice to the Company, but not to any percentage in excess of 9.99%.
The Exercise Price and number of Warrant Shares issuable upon the exercise of the Warrants will be subject to adjustment in the event of any stock dividends, forward or reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrants.
Total gross proceeds to the Company, assuming full exercise of the Warrants will be approximately a minimum of approximately $8,235,000 and up to a maximum of approximately $40,000,000.
The above description of the Warrants does not purport to be complete and is qualified in its entirety by the full text of the “form of” Warrant which is attached hereto as Exhibit 10.2, and incorporated herein by reference.
Placement Agent Compensation
The Special Equities Group, a division of Bradley Woods & Co. Ltd. (“SEG”) and The Benchmark Company (“Benchmark”) (collectively, the “Placement Agents”) will act as co-placement agents for the Offering. The Company has agreed to pay the Placement Agents a cash fee in the aggregate amount of 6.0% of the net proceeds received by the Company at Closing (the “Placement Fee”). The Placement Fee will be split between SEG and Benchmark. Additionally, the Company will, at Closing, grant to the Placement Agents (or their designated affiliates) warrants to purchase common stock (the “Placement Agent Warrants”) in an aggregate amount equal to six percent (6.0%) of the shares of common stock issuable upon conversion of the Series H Preferred Stock issued at Closing. The Placement Agent Warrants will be exercisable immediately upon issuance and will expire five (5) years after the applicable Closing. The Placement Agent Warrants will be exercisable at a price per share equal to $1.65 per warrant share. The Placement Agent Warrants will not be redeemable and may be exercised in whole or in part for “cash” exercise only.
The above description of the Placement Agent Agreements does not purport to be complete and is qualified in its entirety by the full text of the Placement Agent Agreements which are attached hereto as Exhibit 10.3 and Exhibit 10.5, respectively, and incorporated herein by reference.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
In connection with the SPA, prior to the Closing Date of the transaction described in Item 1.01 of this Current Report on Form 8-K, the Company shall file a Certificate of Designation of Series H Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State for the State of Delaware. The Certificate of Designation shall designate a new class of preferred stock as “Series H Convertible Preferred Stock” in the aggregate amount of 40,000 shares. The Series H Convertible Preferred Stock will have a stated value of $1,000 per share of Series H Convertible Preferred Stock and an initial conversion price equal to $1.50. The Series H Convertible Preferred Stock ranks pari passu with the Company’s issued and outstanding Series G Convertible Preferred Stock. The summary of the rights, powers, and preferences of the Series H Convertible Preferred Stock set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.03.
A copy of the Certificate of Designation is attached hereto as Exhibit 4.1 and incorporated herein by reference.
Item 8.01 Other Events
The Company currently intends to put an anti-takeover rights agreement in place.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
4.1 Form of Certificate of Designation for Series H Convertible Preferred Stock
10.1 Form of Securities Purchase Agreement dated December 9, 2019
10.2 Form of Warrant
10.3 SEG Placement Agency Agreement
10.4
Benchmark Placement Agency Agreement
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 10, 2019
TARONIS TECHNOLOGIES, INC.
/s/ Scott Mahoney
By: Scott Mahoney
Its: Chief Executive Officer
FYI
Scott Mahoney
Chief Executive Officer
____________, 2019
Dear Taronis Technologies Shareholder:
We are pleased to inform you that the board of directors of Taronis Technologies, Inc. (“Taronis Technologies”) has approved a plan to pursue a separation of its gas and welding supply retail business from Taronis Technologies through a spin-off of its wholly owned subsidiary, Taronis Fuels, Inc. (“Taronis Fuels”). Taronis Technologies will distribute the shares of Taronis Fuels as a dividend to shareholders of Taronis Technologies on or about December 5, 2019. We expect the Taronis Fuels common stock to be quoted on the OTCQX of the OTC Market Group under the symbol “TRNF” at the time of the spin-off and, assuming such quotation, we expect to up list the Taronis Fuels common stock from the OTCQX to The NYSE American (“NYSE American exchange”) under the symbol “TRNF” within six months following the spin-off date.
As a current shareholder of Taronis Technologies, you will receive five (5) shares of common stock of Taronis Fuels for every one (1) share of common stock of Taronis Technologies that you own and hold as of the record date so long as you continue to hold your shares on the distribution date, as further described in the enclosed Information Statement. Shareholder approval of the distribution is not required, nor are you required to take any action to receive your shares of common stock of Taronis Fuels.
Following completion of the spin-off, common stock of Taronis Technologies, which will continue as a leading clean technology company in the renewable resources and environmental solutions industries, will continue to trade on the Nasdaq Capital Market, subject to Taronis Technologies continued compliance with the Nasdaq Listing Rules, under the symbol “TRNX.”
We invite you to learn more about Taronis Fuels by reviewing the enclosed Information Statement, which describes the spin-off and Taronis Fuels in detail and contains important information about Taronis Fuels, including historical audited and unaudited condensed combined carve-out financial statements.
Thank you for your continued support of Taronis Technologies and your future support of Taronis Fuels.
Sincerely,
Scott Mahoney
Chief Executive Officer
Enclosure
Taronis Technologies, Inc.
300 W. Clarendon Avenue, #230
Phoenix, Arizona 85013
United States
SIGN...I think this is a SIGN of things to come...
"We will definitely be an international firm working with some major clients," said Kay. "This should definitely be the right year for us," he closed."
Article in full:
Miami, FL – December 2, 2019 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, reports on EXXE Group, Inc. (OTC Pink: AXXA).
Exxe Corp (AXXA) is a holding company with a real estate centric focus. Based on current prices, the asset value of the company’s holdings vastly exceeds the existing market capitalization by a factor of more than 10:1, thus offering huge upside to savvy investors! These discrepancies happen from time to time in the market, but they usually do not last for very long as sophisticated investors discover the unique and potentially very profitable opportunity.
What makes the valuation story even more powerful is that these assets are exciting in-demand properties that have a bit of celebrity attached to them and are generating huge revenue growth for the company. Every once in a while, there is a delay in the market where situations like this get overlooked. Then big news or a new quarterly report is released, and the market realizes it has completely mispriced and forgotten about a stock that is way undervalued AND enjoying unmatched growth in its core businesses. These windows typically do not last very long and it appears we are right on the cusp of a major turn in investors awareness regarding Exxe. For these reasons, it appears that Exxe’s market cap is well positioned to at least approach, if not reach the lofty value of its assets.
Make no mistake, Exxe Group is a diversified company in terms of its assets, businesses, and geography. The more than $48.5 million in real estate holdings alone (as of recent 10-Q) are high profile, liquid properties such as luxury, high-end condominiums in Trump Tower. The Company also has valuable media assets that provides Exxe with direct media access to China via their Chinese Film Festival franchise. They even have sustainable environmental operations along with the money to back up any bold venture they choose with their close access to private equity. Highly regarded investment research firm Goldman Small Cap Research projected “revenue will reach $9.2M this year with $670,000 in EBITDA and $33.4M in revenue and $8.4M in EBITDA in 2020. Note these figures do not include contribution from new businesses that may yet be acquired and would have a positive impact on our projections.” Based on these facts it’s not hard to like this story. The numbers alone could double the price of the stock.
Low Risk of Debt Conversion
One major concern OTC investors often have is regarding “toxic”convertible debt on a given company’s books. The Goldman Report doesn’t dissect the debt, but in order to make an informed investment decision it’s important to address the elephant in the room. Yes, there is a tiny amount of convertible debt that totals about $500K but it’s broken into 2 different buckets: old and new. Given its small amount, there isn’t a need to get into deep details of this debt, but it is being easily managed through repayment with a new instrument or extinguishing the debt. Company management has even gone on record saying that their goal was to have this convertible debt paid by the end of the current fiscal year. It seems that there are big investors on the sidelines ready and to eliminate the which bodes well for new shareholders concerned about dilution.
The company has on its books about $47 million in long term low interest debt, which is typical of firms with large real estate interests and is a bit lower than the real estate assets carried on the books. The debt is NOT convertible and in general has very favorable terms to the company with respect to interest averaging between 5-8%. The Company utilizes an innovative and sophisticated acquisition financing strategy which includes the combination of multiple sources of debt and equity. The debt holders are a potpourri of property owners, business owners, investors, and banks. Each of the debt holders had ceded majority control of the asset to the management of AXXA. This means that AXXA management has the flexibility it needs, to sprinkle the funds it receives off the properties to its respective noteholders.
Let that sink in, because the picture being painted here is that there is about $47 million in equity that was just raised inside of this company. These are long term investors interested in the success of the company, happy with their interest rate, and having full confidence in the company managing the assets. It’s a win-win scenario for AXXA management and the property owner and could be a win-win-win scenario as investors pay close attention to the enormous leverage generated by AXXA’s strategy.
A Chasm in Valuation–Set to Narrow
The current market cap of AXXA is $7.0 million yet it has $99.7 million in stockholders’ equity (assets minus liabilities) as of 2Q19, which was announced in mid-November 2019. The question is why the chasm in valuation? They have private equity financing and management’s successful buying binge has been demonstrated by 4 completed acquisitions and 3 more currently under MOU’s. It’s a complete mystery why investors aren’t following the money. Aside from the tiny convertible debt and being overlooked by investors, we arrive at only one plausible explanation. Some investors tend to stay on the sidelines when a company’s financials are in a current unaudited status. Management is working feverishly to audit current and previous financials for public dissemination. Once completed, this step should remove this aforementioned possible roadblock to future stock price gains and market cap gains.
Current Audit Status
The company in the process of becoming fully reporting and just filed a Regulation A+ document for fundraising which provides additional financial validation as its filed on EDGAR with the SEC. This filing provides Exxe Group with access to crowdfunding. AXXA is essentially a consolidation play as they take private equity money, find value propositions in exciting market sectors and roll them into the holding company. The step to becoming fully reporting should set the stage for a NASDAQ uplisting.
The evidence suggests that the stock price’s upside has been held in check only in the near term by the convertible notes, the audit status and the fact that it has been overlooked. But it seems like this chapter in the company’s history is drawing to a close by year end. The current stock price represents extreme value and nominal risk for the long-term investors with, assuming no growth at all, over 100% upside potential. Moreover, once released, those sideline investors will miss the boat on the big, early run, and then likely help take the stock to new highs.
Exxe Group Represents Best Valuation in REIT Sector
One way to value Exxe Group is to compare it with its peer group. The top REITs trade based on a valuation metric called Adjusted Funds From Operations (AFFO). The adjusted number is needed to normalize the earnings for depreciation. For most businesses that purchase assets it is standard practice to depreciate them because they are using them in the course of their business operations but for a REIT factoring depreciation isn’t a good gauge of performance. The Price/AFFO is the REIT’s equivalent of a Price to Earnings Ratio (P/E) and the average multiple expands and contracts based on the health of the real estate market. Last year the average Price/AFFO was 23.0.
Please see the chart at:
https://emerginggrowth.com/why-exxe-groups-otc-pink-axxa-valuation-is-set-to-move-markedly-higher/
As evidenced by this table, Exxe Group offers the lowest Price/AFFO valuation, signaling lower inherent risk and potentially the greatest upside. Investors want to avoid buying into a multiple that is too high but a situation that offers major upside potential. Clearly, Exxe offers the best of both worlds. As you can see by the chart, Exxe group (OTC Pink: AXXA) has the lowest Price / AFFO by far.
Asset Growth Could Fuel Takeover Speculation
REIT’s have metrics that measure their asset growth because that’s ultimately how they make their money. Right now, AXXA is not on the radar of the top REIT’s but if they get to the billion-dollar mark heads will start to turn. According to Goldman Research the company should eclipse $250 million in assets in the coming year, which would make them a contender for a buyout in 1 – 2 years as the REIT’s continue their consolidation.
Goldman Small Cap Research Forecast
Goldman estimates are actually conservative in terms of valuation because if AXXA has any multiple expansion to the average of 23X then that increases the market cap to $190 million or $.45/share. The qualifier is the thing that investors need to pay attention to because these estimates assume no new business. There appears to be a very low risk that the stock will continue to trade at these depressed valuations.
The point of this article is this: As the audit is completed and additional transactions occur in conjunction with continued strong operating results, and reaching the Goldman Research forecasts, it is clear that the share price will likely be substantially higher than current levels.
Phoenix, Arizona--(Newsfile Corp. - December 3, 2019) - The Stock Day Podcast welcomed StrikeForce Technologies, Inc. (OTC Pink: SFOR) ("the Company"), a company that helps to prevent Cyber theft and data security breaches for consumers, corporations, and government agencies. CEO of the Company, Mark Kay, joined Stock Day host Everett Jolly.
Jolly began the interview by asking about the Company's annual meeting. "It went very well," shared Kay. "We just completed a major deal recently," said Kay, adding that the Company also shared news of additional projects which has increased shareholder interest.
Jolly then commented on the Company's substantial revenue growth, and asked about the potential of their upcoming quarters. "We just closed one of our most major deals that we've been working on for over three years," said Kay, adding that the deal was facilitated through their strategic partner, ACS. He then elaborated on an agreement that was secured by ACS involving the world's largest credit card processor. When discussing the Company's guarded ID Computer, Kay also explained that the Company's flagship product is being bundled into a PCI compliance program.
"We will be getting our first payment probably around the end of January or the 1st of February," said Kay. "It will be growing every month," he added. "Two to three million merchants will be onboard - this is a huge deal."
Kay then shared that the Company is also working to secure additional agreements with major banks for the use of their software. "We see the company starting to grow massively over the next six months," said Kay, adding that revenue increases will begin to appear during this time. "We're looking very strong and we feel really good about what we have."
Jolly then asked about the Company's patent lawsuits. Kay explained that the Company is currently awaiting new regulations to come to fruition which will allow them to move forward with the patent lawsuits. "It's just timing," said Kay, adding that the Company currently has three pending patents. "We still feel good about the lawsuits," shared Kay. "We're not giving up on it."
To close the interview, Kay expressed his excitement for the incredible potential of the Company's recently closed deal through ACS, which will begin to generate revenue in the coming months. "We will definitely be an international firm working with some major clients," said Kay. "This should definitely be the right year for us," he closed.
To hear Mark Kay's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7440233-strikeforce-technologies-inc-joins-the-stock-day-podcast-to-discuss-the-closing-of-a-major-deal
Too much noise softens the memory...lol
GLTY
SLAM
STONEY CREEK, Ontario--(BUSINESS WIRE)--November 25, 2019--
Airtrona International (ARTR) is pleased to announce it has signed a Letter of Intent and merger agreement with Canadian based Arc Medical Devices. The agreement is based in part on the cancellation and or a suitable resolution towards the dissolution of prior restrictive shares held by old Management. The company will then acquire a special series of preferred shares that will represent controlling interest moving forward. Upon successful completion of the term agreement Arc Medical Devices will utilize it's controlling interest to move forward with the necessary compliance requirements, reinstatement, and updates to the company.
This shareholder update may contain certain forward-looking statements regarding future circumstances. These forward-looking statements are based upon the Company's current expectations and assumptions and are subject to various risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. Actual results, events, and performance may differ.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191125005120/en/
if my share count can handle the RS I should stay in until after the dust settles...if not I would be taking my current gains or losses and sell today. STRICTLY my own opinion based upon past PHOT history.
GLTY in whatever you decide to do.
SLAM
their website has NOT been updated...but FINRA is. Been around this stock for several years...it is strictly a short term buy on the dips to make a small profit. The same in and out purchases will resume after the RS.
Nice to see some movement today even if the volume is a little low.
GLTA
SLAM
That's great to hear...but you said the same thing last week and you are still here????
GLTY
SLAM
IDK...with the steady decline over the last few months I would think maybe some weak hands might want to jump out and not wait for .01...but I would prefer the rapid rise to continue.
GLTY
SLAM
Very nice and concise explanation sorc92...really appreciate the information...thanks for making that an easy read!!
GLTY
SLAM
New 8K this morning....
There should be a minor correction today...
GLTA
SLAM
you have been saying the same old line since 2018. Sense you are such a seasoned investor you probably know that if you put in a sell order for .0001 your shares will be purchased...lol
Tooooooo funny
Lllllooooolllll
2 separate companies. First Data is part of Wells Fargo...DSS is not. Anyone is welcomed to give their respective IR a call to confirm.
© 2019 First Data Corporation. All rights reserved.
First Data Merchant Services, LLC is a registered ISO of Wells Fargo Bank, N.A., Concord, CA; Deutsche Bank AG, New York, NY; BBVA USA, Birmingham, AL; MVB Bank, Fairmont, WV; and MetaBank, Sioux Falls, SD. Review First Data’s Legal Policy.
Document Security Systems, Inc. (DSS)
200 Canal View Blvd.
Suite 300
Rochester, NY 14623
Email: info@dsssecure.com
Phone: 585-325-3610 Fax: 585-325-2977
Privacy Policy | Terms of Use | Contact Us | Home
Document Security Systems, Inc. © 2019 | All trademarks referenced herein are the property of their respective owners.
MRbags...I would be most happy to join you at your retirement party...and I will be happy to buy the first round!!!!!!!!!!
Best regards,
SLAM
10 Q released
Thanks OTC...that is a great link with all the basics.
Thanks for posting.
GLTA
SLAM
So you think that ANY message board has ANY impact on stock prices...now that's the real joke...
GLTA
SLAM
Ditto for NateduhGreat
So you are a Flipper...who cares???? I flip some stocks as well...but I don't need anyone to prove me right or wrong.
GLTA
SLAM
WOW...thanks for that advice..woosh
I would think the date of fund activation would be a material event, and providing that information to an individual would be more along the lines of insider trading. It is better that he did not respond to that question. Thanks for posting the conversation for us to see.
GLTA
SLAM
Whereas I would love to see JCP come back and sail higher...I just find it hard to see where any B&M has a chance of competing with online technologies that drive the marketplace. I truly like shopping there but must admit most of my JCP purchases are on-line due to the need for "tall" sizes that are not kept in the local stores.
IF they turn this around it will be a historical happening. I wish them luck. For now I am just playing the dips until the fiscal year end numbers are produced.
GLTA
SLAM
NEEDS TO BE "BIT" A LITTLE HARDER...OUCH!
INTERESTING DATA OVER THE PAST 24 HOURS.
MOST READ:
DBMM
ALPP
PHIL
AXXA
MOST POSTED:
DBMM
ALPP
AXXA
PHIL